NCT00669851

Brief Summary

This study evaluated and optimized settings for, and evaluated the performance of, AI-700-enhanced echocardiographic imaging on several ultrasound imaging platforms, as well as collected additional safety data for AI-700 in healthy volunteers and stable cardiac patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at below P25 for phase_3 coronary-artery-disease

Timeline
Completed

Started Nov 2006

Shorter than P25 for phase_3 coronary-artery-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2006

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2007

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

April 29, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 1, 2008

Completed
Last Updated

May 1, 2008

Status Verified

April 1, 2008

First QC Date

April 29, 2008

Last Update Submit

April 29, 2008

Conditions

Keywords

coronary artery diseaseechocardiographycardiac imagingheart diseaseultrasound contrast agentmyocardial contrast enhancementmyocardial perfusion

Outcome Measures

Primary Outcomes (3)

  • Image quality of echocardiographic data collected via several ultrasound imaging platforms

  • For Cohort B, the duration of MCE following the first 0.04 mL/kg dose of AI-700

  • Safety of AI-700 administered IV to healthy volunteers and suspected CAD patients

Interventions

AI-700DRUG

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • For Cohort A, men and non-pregnant/non-lactating women in good health who are 18 to 70 years of age and who have a low chance of CAD will be enrolled.
  • For Cohort B, men and non-pregnant/non-lactating women in good health who are 18-70 years of age who have had a prior MI and/or coronary artery revascularization intervention \>90 days before AI-700 administration, without new or recurrent angina will be enrolled.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Acusphere, Inc.

Watertown, Massachusetts, 02472, United States

Location

Related Links

MeSH Terms

Conditions

Coronary Artery DiseaseHeart Diseases

Interventions

perfluorobutane

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 29, 2008

First Posted

May 1, 2008

Study Start

November 1, 2006

Study Completion

March 1, 2007

Last Updated

May 1, 2008

Record last verified: 2008-04

Locations